FundingRounds, leads & terms
Isomorphic Labs raises $5B Series C co-led by Greenoaks and Sequoia to move AI-designed drugs into clinical trials
DeepMind spinout Isomorphic Labs has raised a $5 billion Series C, co-led by Greenoaks and Sequoia, which press reports call biotech's largest private round. The company aims to move AI-designed oncology and immunology candidates into trials but has named none publicly.
From the TechCrunch · Fundraising article of November 17, 2026 and cited sources: Greenoaks and Sequoia co-led the $5 billion round. [1] [2] [3] [12]
SOURCES[1] Isomorphic Labs raises $5B as it looks to take drug… techcrunch.com[2] Isomorphic Labs – Series C announcement isomorphiclabs.com[3] BioSpace – record $5B Series C biospace.com
AI-assisted, not human-edited. Methodology Corrections Who owns this site
- Original source
- TechCrunch · Fundraising article, independent perspective
- Brief by
- AT Pulse research desk AI-assisted; publisher and contact on the desk page
- When
- November 17, 2026 article published
- Covered
- Nov 18 edition
- Evidence
- 13 sources across 12 sites
- 1Isomorphic Labs raises $5B as it looks to take drug…techcrunch.com
- 2Isomorphic Labs – Series C announcementisomorphiclabs.com
- 3BioSpace – record $5B Series Cbiospace.com
- 4Isomorphic Labs – IsoDDEisomorphiclabs.com
- 5The Decoder – IsoDDE claimsthe-decoder.com
- 6AAP/Cision – Series B releaseaap.com.au
Reach: not measured yet

Greenoaks and Sequoia co-led the $5 billion round. Andreessen Horowitz joined as a new investor, and all existing backers put in more money. BioSpace says it beats Altos Labs' $3 billion raise in 2022 as the largest private biotech financing. Isomorphic previously raised $600 million in March 2025 and $2.1 billion in May 2026, and press reports put its total at about $7.7 billion. [1] [2] [3] [12]
Isomorphic did not disclose its valuation. Earlier in November, Bloomberg cited people familiar with the matter as saying the company was in talks to raise about $5 billion at a valuation of $40–50 billion. [10]
The money is meant to take AI-designed oncology and immunology candidates into clinical trials. Isomorphic works with Eli Lilly, Novartis and Johnson & Johnson. Demis Hassabis still leads Isomorphic after stepping down as DeepMind CEO in August to become DeepMind's chair and Alphabet's chief scientist. [1] [8] [9]
The company's IsoDDE drug design engine is reported by the company to be more than twice as accurate as AlphaFold 3 on the hardest new protein–ligand cases. Its architecture, training data and weights are undisclosed, and outsiders can use it only through partnerships. Competitor Deep Origin says it reached similar docking results earlier. [4] [5] [11]
The company confirms the round size but not the valuation. If the reported valuation is accurate, investors are pricing a preclinical biotech like a frontier AI lab. Its first trial entries will test whether AI-led drug design justifies that premium.
Sources gathered; writing the dossier now.
Executive brief
Isomorphic Labs, the drug-design company spun out of DeepMind, has raised $5 billion in a Series C. BioSpace calls it the largest private round in biotech history, beating Altos Labs' $3 billion in 2022. The company has not named a single drug candidate or disclosed any clinical program. The company did not disclose its valuation. Bloomberg earlier reported, citing unnamed sources, a target of about $50 billion. The money is meant to take AI-designed oncology and immunology candidates into clinical trials. That step is still pending, and the company has missed this target date before.
Read the full section
Isomorphic Labs, the drug-design company spun out of DeepMind, has raised $5 billion in a Series C. BioSpace calls it the largest private round in biotech history, beating Altos Labs' $3 billion in 2022. The company has not named a single drug candidate or disclosed any clinical program. Greenoaks and Sequoia co-led the round. The company did not disclose its valuation. Bloomberg earlier reported, citing unnamed sources, a target of about $50 billion. The money is meant to take AI-designed oncology and immunology candidates into clinical trials. That step is still pending, and the company has missed this target date before.
What changed and event timeline
IsoDDE unveiled
Isomorphic published a technical report on its drug design engine (IsoDDE). It claims more than double AlphaFold 3's accuracy on the hardest new protein–ligand systems. The report does not describe the architecture.
More detail
$2.1B Series B
Thrive Capital led the round, joined by Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund. The company again said it was aiming for clinical trials by end-2026.
Hassabis leaves the DeepMind CEO role
He became DeepMind's chair and Alphabet's chief scientist, and kept leading Isomorphic. Koray Kavukcuoglu took over DeepMind's day-to-day operations.
More detail
Valuation talks reported
Bloomberg, citing people familiar with the matter, reported talks to raise about $5B at a valuation of $40–50B.
$5B Series C announced
Greenoaks and Sequoia co-led, a16z joined as a new investor, and every existing backer reinvested. The company did not disclose the valuation.
More detail
Capabilities and access
- IsoDDE is a proprietary engine that combines several models.
- The company has published no version number, model size or access terms. Competitor Deep Origin says IsoDDE is available only through Isomorphic's partnerships (Deep Origin).
- Its pharma partners are Eli Lilly, Novartis and Johnson & Johnson (TechCrunch).
Read the full section
- IsoDDE is a proprietary engine that combines several models. Isomorphic says it covers four tasks: protein–ligand structure prediction, antibody–antigen interface modelling, binding-affinity estimation and finding drug-binding pockets (Isomorphic).
- The company has published no version number, model size or access terms. Competitor Deep Origin says IsoDDE is available only through Isomorphic's partnerships (Deep Origin).
- Its pharma partners are Eli Lilly, Novartis and Johnson & Johnson (TechCrunch).
Technical analysis for researchers and developers
- Benchmarks reported (Isomorphic):
- Runs N' Poses: more than double AlphaFold 3's accuracy in the 0–20% similarity bin, meaning test cases least like the training data.
- Antibody–antigen: 2.3× AlphaFold 3 and 19.8× Boltz-2 at a strict accuracy cutoff (DockQ above 0.8).
Read the full section
- Benchmarks reported (Isomorphic):
- Runs N' Poses: more than double AlphaFold 3's accuracy in the 0–20% similarity bin, meaning test cases least like the training data.
- Antibody–antigen: 2.3× AlphaFold 3 and 19.8× Boltz-2 at a strict accuracy cutoff (DockQ above 0.8).
- Binding affinity: reported to beat physics-based free-energy (FEP) methods on the FEP+4, OpenFE and CASP16 benchmarks.
- Not disclosed: architecture, training data, data cutoff dates or weights. Some comparisons appear only as graphs (The Decoder).
- Reproducibility: outsiders cannot re-run any of these results. Unlike AlphaFold 3, IsoDDE cannot be used as a baseline in other people's work.
Claims and evidence
- Round size and leads ($5B; Greenoaks and Sequoia): company-announced (Isomorphic). TechCrunch, BioSpace and R&D World report the same figures. No regulatory filing has confirmed them.
- About $50B valuation: reported only by Bloomberg, from unnamed sources. The company has not confirmed it.
- Total raised of about $7.7B, and Alphabet owning more than 75%: both come from press reports (BioSpace; R&D World).
Read the full section
- Round size and leads ($5B; Greenoaks and Sequoia): company-announced (Isomorphic). TechCrunch, BioSpace and R&D World report the same figures. No regulatory filing has confirmed them.
- About $50B valuation: reported only by Bloomberg, from unnamed sources. The company has not confirmed it.
- Total raised of about $7.7B, and Alphabet owning more than 75%: both come from press reports (BioSpace; R&D World).
- "Positive preclinical results": self-reported, with no data published (TechCrunch).
- IsoDDE benchmark gains: vendor-reported, with no independent replication.
- Hassabis's "unprecedented precision and speed" quote: the CEO describing his own company's engine (BioSpace).
Context and prior work
Read the full section
- Isomorphic was spun out of DeepMind in 2021. Its work builds on AlphaFold, which won Hassabis and John Jumper a share of the 2024 Nobel Prize in Chemistry (TechCrunch).
- Its funding history: $600M in its first external round (March 2025), $2.1B in May 2026, now $5B (BioSpace).
- McKinsey estimates, as cited by R&D World, put AI drug-discovery funding at $4.1B in 2023 and $8.4B in 2025.
Limitations, safety and contested findings
- Timeline slippage: the clinical-trial target moved from 2025 to end-2026, and about six weeks of 2026 were left when the round was announced (R&D World).
- Against industry trend: BioSpace notes the round went against the trend of investors favouring more mature, lower-risk drug assets (BioSpace).
- Disputed benchmark lead: Deep Origin, a competitor, says its own docking model passed 90% success on PoseBusters months earlier.
Read the full section
- Timeline slippage: the clinical-trial target moved from 2025 to end-2026, and about six weeks of 2026 were left when the round was announced (R&D World).
- Against industry trend: BioSpace notes the round went against the trend of investors favouring more mature, lower-risk drug assets (BioSpace).
- Disputed benchmark lead: Deep Origin, a competitor, says its own docking model passed 90% success on PoseBusters months earlier. It calls IsoDDE's results "catching up" and argues benchmarks are only table stakes (Deep Origin).
Business and practitioner implications
- For investors: at a reported (not confirmed) ~$50B, Isomorphic is priced like a frontier AI lab, not a preclinical biotech.
- For pharma: access to IsoDDE comes through partnership deals, not an API. That favours big companies like Lilly, Novartis and J&J over smaller biotechs.
- For developers and researchers: open models such as AlphaFold 3 and Boltz-2 remain the baselines anyone can reproduce.
Read the full section
- For investors: at a reported (not confirmed) ~$50B, Isomorphic is priced like a frontier AI lab, not a preclinical biotech. Its first trial readouts will test whether that premium holds.
- For pharma: access to IsoDDE comes through partnership deals, not an API. That favours big companies like Lilly, Novartis and J&J over smaller biotechs.
- For developers and researchers: open models such as AlphaFold 3 and Boltz-2 remain the baselines anyone can reproduce. IsoDDE's numbers should be read as vendor-reported until it is evaluated externally.
- For the field: Hassabis now runs Isomorphic full-time instead of DeepMind (Fortune). That signals Alphabet sees drug design as a priority use of its AI.
The source trail.
Sources (13)
Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
Article text retrieved; extracted text may omit tables or interactive elements.
techcrunch.com